- Quest Diagnostics (DGX, Financial) beats first-quarter earnings estimates with a notable revenue increase.
- Analysts project an average price target of $180.78, indicating a potential 11.69% upside.
- The company's average brokerage recommendation suggests an "Outperform" status.
Quest Diagnostics (DGX) recently announced its financial results for the first quarter. The company reported non-GAAP earnings per share of $2.21, which surpassed market expectations by $0.06. Revenue for the quarter stood at $2.65 billion, marking a 12.1% increase compared to the same period last year, and beating forecasts by $20 million. For the full-year 2025 guidance, Quest Diagnostics anticipates revenues ranging between $10.70 billion and $10.85 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.